Kensey Nash (KNSY) Enters Settlement with St. Jude (STJ) Over Angio-Seal, Adjusts Outlook for Q3, Q4, FY12; Guides FY13

March 19, 2012 6:46 AM EDT
Get Alerts KNSY Hot Sheet
Price: $38.46 --0%

Financial Fact:
Royalty income: 6.1M

Today's EPS Names:
PG, CFG, GE, More
Trade KNSY Now!
Join SI Premium – FREE
Kensey Nash Corporation (Nasdaq: KNSY) today announced that the Company has entered into a settlement agreement with St. Jude Medical (NYSE: STJ) which resolves all disputes between the two companies relating to the Angio-Seal vascular closure device licenses, as well as other related claims. As part of the settlement agreement, the companies also agreed to extend their collagen supply agreement through 2017 and expand the minimums to be provided over the contract term to five million units.

Under the terms of the agreement, Kensey Nash will receive $39 million from St. Jude, payable in 12 equal quarterly payments beginning March 31, 2012, in lieu of all future royalties for the Angio-Seal and all other related claims. The Company expects to recognize the $39 million as royalty revenue on a straight line basis beginning January 2012 through April 2014, which is the expiration of the last to expire of patents exclusively licensed by Kensey Nash to St. Jude under the settlement agreement and acknowledged by both parties to cover the Angio-Seal device. Additionally, Kensey Nash will continue to be the exclusive outside supplier of collagen for the Angio-Seal device through 2017. The approximate value of the minimum orders under the collagen supply agreement over the five year extension is $31 million.

The company also updated its outlook. Sees third-quarter revs of $16.1 - $16.3 million and adjusted EPS of 33 - 35 cents per share. The Street sees EPS of 23 cents and revs of $20.5 million.

Sees fourth-quarter revs of $17.5 - $18.0 million and EPS of 43 to 45 cents. The consensus sees EPS of 26 cents and revs of $21.25 million.

Sees fiscal 2012 revs of $65.5 - $66.3 million and EPS of $1.59 - $1.63. The Street is modeling revs of $84.8 million and EPS of $1.33.

The Company is providing preliminary top level guidance for fiscal 2013 which includes the impact of the settlement, and the expected collagen orders under the new supply agreement. Total fiscal 2013 revenues are expected to be approximately $100 million, and earnings per share are expected to exceed $2.00 per share.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Guidance, Hot Guidance, Litigation

Related Entities


Add Your Comment